Market Cap 2.58B
Revenue (ttm) 560.23M
Net Income (ttm) -569.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -101.60%
Debt to Equity Ratio 0.00
Volume 2,025,600
Avg Vol 1,865,444
Day's Range N/A - N/A
Shares Out 94.54M
Stochastic %K 66%
Beta 0.26
Analysts Strong Sell
Price Target $87.00

Company Profile

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevi...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 483 8800
Address:
60 Leveroni Court, Novato, United States
RunnerSignals
RunnerSignals Jul. 28 at 7:42 PM
Analysts are getting bullish! $NKE $TXN $CLSK $PD $RARE all caught fresh upgrades today https://stocksrunner.com/news/2025-07-28-stock-upgrades-today-top-5-picks-with-the-strongest-upside-potential
0 · Reply
Quantumup
Quantumup Jul. 28 at 11:47 AM
H.C. Wainwright assumed coverage on $RARE Buy/$80. $MREO $XBI H.C. Wainwright said, "We are assuming coverage of Ultragenyx Pharmaceuticals with a Buy rating and 12-month price target of $80. In our view, Ultragenyx shares represent an attractive opportunity at current levels, down 35% YTD vs. only a 2.7% decline in the benchmark $XBI index. From our vantage point, Ultragenyx shares have primarily come under pressure due to investor disappointment in the interim readout from the pivotal Orbit trial of its candidate UX143 (setrusumab), which is being developed for treatment of osteogenesis imperfecta (Ol). While originally sentiment was buoyed by the expectation that the interim readout would be sufficient to support regulatory submission and approval, Ultragenyx announced earlier this month that the Orbit trial would instead progress toward a final analysis consistent with the original statistical plan, with results slated to be released around the end of this year. H.C. Wainwright added:
0 · Reply
JarvisFlow
JarvisFlow Jul. 28 at 10:30 AM
HC Wainwright & Co. updates rating for Ultragenyx Pharmaceutical ( $RARE ) to Buy, target set at 80.
0 · Reply
flanny111
flanny111 Jul. 26 at 3:42 AM
$RARE not sure if I should hold this through ER. They’ve already had two pieces of bad news very recently so maybe a lot of the downside is limited
0 · Reply
GunnarMeister
GunnarMeister Jul. 25 at 2:18 AM
$RARE back in the 26$. Needs. white knight asap
0 · Reply
KayleighMcEnany_Real
KayleighMcEnany_Real Jul. 24 at 3:45 PM
$RARE Risk to reward seems decent here.
0 · Reply
Andrea31
Andrea31 Jul. 24 at 1:08 PM
$RARE I believe in a good offer to buy RARE
0 · Reply
Shazreen
Shazreen Jul. 24 at 12:48 PM
0 · Reply
jewell69
jewell69 Jul. 24 at 12:38 AM
for all the haters out there, occasionally I take a loss. sold 75 $RARE today 7/23 at a loss but got a whopping 28.14. Paid 29.51 and 29.23 for it. it ended at 28.01 so I feel pretty good about it. I still own 101 but felt like I HAD 2 UNLOAD some on a super up day. also, lost real money on $MLYS 7 15 b 130 at 14.57 7 23 today 7 130 at 13.36 did everybody see that $EUFN Europe Financials was up tons 4.17% ditto France $EWQ up 3.1% trimmed $SCJ today 7/23 at a price higher than the close s 185 at 86.5535 It closed at 86.46
0 · Reply
KayleighMcEnany_Real
KayleighMcEnany_Real Jul. 23 at 3:32 PM
$RARE Under 30 is an easy buy.
0 · Reply
Latest News on RARE
Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline

Apr 16, 2025, 9:49 AM EDT - 3 months ago

Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline


Ultragenyx to Participate at Investor Conferences in March

Feb 24, 2025, 4:30 PM EST - 5 months ago

Ultragenyx to Participate at Investor Conferences in March


Ultragenyx to Participate in Investor Conferences in December

Nov 26, 2024, 4:30 PM EST - 8 months ago

Ultragenyx to Participate in Investor Conferences in December


Ultragenyx: Ready For More Growth After Q3 Earnings Beat

Nov 12, 2024, 11:12 AM EST - 9 months ago

Ultragenyx: Ready For More Growth After Q3 Earnings Beat


Ultragenyx to Participate in Investor Conferences in September

Aug 29, 2024, 4:30 PM EDT - 11 months ago

Ultragenyx to Participate in Investor Conferences in September


RunnerSignals
RunnerSignals Jul. 28 at 7:42 PM
Analysts are getting bullish! $NKE $TXN $CLSK $PD $RARE all caught fresh upgrades today https://stocksrunner.com/news/2025-07-28-stock-upgrades-today-top-5-picks-with-the-strongest-upside-potential
0 · Reply
Quantumup
Quantumup Jul. 28 at 11:47 AM
H.C. Wainwright assumed coverage on $RARE Buy/$80. $MREO $XBI H.C. Wainwright said, "We are assuming coverage of Ultragenyx Pharmaceuticals with a Buy rating and 12-month price target of $80. In our view, Ultragenyx shares represent an attractive opportunity at current levels, down 35% YTD vs. only a 2.7% decline in the benchmark $XBI index. From our vantage point, Ultragenyx shares have primarily come under pressure due to investor disappointment in the interim readout from the pivotal Orbit trial of its candidate UX143 (setrusumab), which is being developed for treatment of osteogenesis imperfecta (Ol). While originally sentiment was buoyed by the expectation that the interim readout would be sufficient to support regulatory submission and approval, Ultragenyx announced earlier this month that the Orbit trial would instead progress toward a final analysis consistent with the original statistical plan, with results slated to be released around the end of this year. H.C. Wainwright added:
0 · Reply
JarvisFlow
JarvisFlow Jul. 28 at 10:30 AM
HC Wainwright & Co. updates rating for Ultragenyx Pharmaceutical ( $RARE ) to Buy, target set at 80.
0 · Reply
flanny111
flanny111 Jul. 26 at 3:42 AM
$RARE not sure if I should hold this through ER. They’ve already had two pieces of bad news very recently so maybe a lot of the downside is limited
0 · Reply
GunnarMeister
GunnarMeister Jul. 25 at 2:18 AM
$RARE back in the 26$. Needs. white knight asap
0 · Reply
KayleighMcEnany_Real
KayleighMcEnany_Real Jul. 24 at 3:45 PM
$RARE Risk to reward seems decent here.
0 · Reply
Andrea31
Andrea31 Jul. 24 at 1:08 PM
$RARE I believe in a good offer to buy RARE
0 · Reply
Shazreen
Shazreen Jul. 24 at 12:48 PM
0 · Reply
jewell69
jewell69 Jul. 24 at 12:38 AM
for all the haters out there, occasionally I take a loss. sold 75 $RARE today 7/23 at a loss but got a whopping 28.14. Paid 29.51 and 29.23 for it. it ended at 28.01 so I feel pretty good about it. I still own 101 but felt like I HAD 2 UNLOAD some on a super up day. also, lost real money on $MLYS 7 15 b 130 at 14.57 7 23 today 7 130 at 13.36 did everybody see that $EUFN Europe Financials was up tons 4.17% ditto France $EWQ up 3.1% trimmed $SCJ today 7/23 at a price higher than the close s 185 at 86.5535 It closed at 86.46
0 · Reply
KayleighMcEnany_Real
KayleighMcEnany_Real Jul. 23 at 3:32 PM
$RARE Under 30 is an easy buy.
0 · Reply
JohnGod
JohnGod Jul. 23 at 2:38 PM
$RARE i dont see any news?🧐
2 · Reply
memphisved
memphisved Jul. 23 at 2:28 PM
$RARE holding [email protected] let’s go
0 · Reply
flanny111
flanny111 Jul. 23 at 12:44 PM
$RARE this stock moves at a snails pace
0 · Reply
JohnSmith791
JohnSmith791 Jul. 23 at 6:39 AM
$RARE Still tracking names with trend alignment
0 · Reply
gauravknayak
gauravknayak Jul. 21 at 4:24 PM
$RARE this is so sad that because of $SRPT every gene therapy company is going to pay price. Though long term this is a winner and I believe it will be cash flow positive by 2027 and then todays buys will look like steal. If you buy here do not expect a quick double. The data and science is good its just going to take long time for recovery.
3 · Reply
LDT79
LDT79 Jul. 21 at 2:30 PM
$RARE this can never stay green now - traders, short sellers all over the place
0 · Reply
JohnSmith791
JohnSmith791 Jul. 21 at 6:42 AM
$RARE Avoiding setups with erratic price action
0 · Reply
GunnarMeister
GunnarMeister Jul. 20 at 10:19 PM
$RARE 25$ next week??
0 · Reply
JackSch
JackSch Jul. 18 at 8:03 PM
$RARE took my loss and moved on to a different sector. With the Proud Boys in charge no one will ever make a penny in this sector. Good luck to you all!
2 · Reply
gauravknayak
gauravknayak Jul. 18 at 7:52 PM
$RARE For all this cranage there is only one company to be blamed and that is $SRPT this idiot company with its garbage drug dragged every company who are trying to do better gene therapy for patients. $SRPT should be banned, and its CEO should be prosecuted for all the lies this idiot has said this whole time and even pressured the FDA to approve its untested therapies with justifications that there is nothing else for these patients. Better just give saline drops in name of medicine at least you won't kill anybody.
0 · Reply
dturkur
dturkur Jul. 18 at 7:52 PM
$RARE About to go under 26
0 · Reply
minchak
minchak Jul. 18 at 6:15 PM
$RARE incredibly undervalued at this point, sentiment has completely taken over
0 · Reply